These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27718032)

  • 1. Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial?
    Huang Y; Alzahrani NA; Liauw W; Traiki TB; Morris DL
    Ann Surg Oncol; 2017 Jan; 24(1):176-183. PubMed ID: 27718032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei].
    Lei ZY; Ding BH; Wu QY; Luo JL; Li Z; Wang T; Wang YS; Chen YX; Huang LF; He JF; Yang XS; Guan TP; Ruan Q; Wang JH; Tang HS; Wang J; Cui SZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1179-1186. PubMed ID: 38110280
    [No Abstract]   [Full Text] [Related]  

  • 3. Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China.
    Wang B; Ma R; Shi G; Fan X; Rao B; Xu H
    Orphanet J Rare Dis; 2024 Jan; 19(1):8. PubMed ID: 38178189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Waikato, Aotearoa New Zealand: a 12-year experience.
    Qin RX; Lim JH; Ly J; Fischer J; Smith N; Karalus M; Wu L; van Dalen R; Lolohea S
    ANZ J Surg; 2024 Apr; 94(4):621-627. PubMed ID: 37994292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of causes and prognostic impact of tube occlusion during hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei.
    Liu Q; Jiao J; Li C; Chen Y; Wang B; Shi J; Yu G
    World J Surg Oncol; 2024 May; 22(1):134. PubMed ID: 38769546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
    Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
    JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin.
    Kung V; Delisle M; Alves S; Mohamed F; Cecil T; Moran B
    Eur J Surg Oncol; 2023 Nov; 49(11):107045. PubMed ID: 37677915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience.
    Narasimhan V; Wilson K; Britto M; Warrier S; Lynch AC; Michael M; Tie J; Akhurst T; Mitchell C; Ramsay R; Heriot A
    J Gastrointest Surg; 2020 Apr; 24(4):899-906. PubMed ID: 31090036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit.
    Bhutiani N; Grotz TE; Concors SJ; White MG; Helmink BA; Raghav KP; Taggart MW; Beaty KA; Royal RE; Overman MJ; Matamoros A; Scally CP; Rafeeq S; Mansfield PF; Fournier KF
    Ann Surg Oncol; 2024 Jan; 31(1):614-621. PubMed ID: 37872456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative.
    Nizam W; Fackche N; Pessoa B; Kubi B; Cloyd JM; Grotz T; Fournier K; Dineen S; Veerapong J; Baumgartner JM; Clarke C; Patel SH; Wilson GC; Lambert L; Abbott DE; Vande Walle KA; Lee B; Raoof M; Maithel SK; Russell MC; Zaidi MY; Johnston FM; Greer JB
    J Gastrointest Surg; 2022 Feb; 26(2):414-424. PubMed ID: 34506026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study.
    Trecourt A; Bakrin N; Glehen O; Gertych W; Villeneuve L; Isaac S; Benzerdjeb N; Fontaine J; Genestie C; Dartigues P; Leroux A; Quenet F; Marchal F; Odin C; Khellaf L; Svrcek M; Thierry S; Augros M; Omar A; Devouassoux-Shisheboran M; Kepenekian V;
    Ann Surg Oncol; 2024 May; 31(5):3325-3338. PubMed ID: 38341381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-step cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei with high peritoneal carcinomatosis index.
    Trilling B; Brind'Amour A; Hamad R; Tremblay JF; Dubé P; Mitchell A; Sidéris L
    World J Surg Oncol; 2021 Feb; 19(1):60. PubMed ID: 33622339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of pseudomyxoma peritonei arising from a perforated intraductal papillary mucinous neoplasm that underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Yoshizaki Y; Gohda Y; Inagaki F; Kataoka A; Takemura N; Miyazaki H; Igari T; Kiyomatsu T; Yano H; Kokudo N
    Clin J Gastroenterol; 2024 Feb; 17(1):188-197. PubMed ID: 37980306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-Grade Pseudomyxoma Peritonei Behaving as a High-Grade Disease: A Case Series and Literature Review.
    Bangeas P; Kyziridis D; Kalakonas A; Tentes AA
    Curr Oncol; 2023 Nov; 30(11):9996-10006. PubMed ID: 37999146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the optimum post treatment surveillance imaging protocol for low-grade appendiceal mucinous neoplasms and pseudomyxoma peritoneii?
    Dempsey PJ; Power JW; Yates AH; Martín-Román L; Aird JJ; Mulsow J; Fenlon HM; Cronin CG
    Br J Radiol; 2024 Aug; 97(1160):1405-1412. PubMed ID: 38749003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Blackham AU; Swett K; Eng C; Sirintrapun J; Bergman S; Geisinger KR; Votanopoulos K; Stewart JH; Shen P; Levine EA
    J Surg Oncol; 2014 Jun; 109(7):740-5. PubMed ID: 24375188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of early postoperative intraperitoneal 5-fluorouracil with index cytoreduction improves survival with secondary cytoreductive surgery.
    Sugarbaker PH; Chang D
    J Surg Oncol; 2024 Feb; 129(2):349-357. PubMed ID: 37822274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogenic Blood Transfusion Is an Independent Predictor of Poorer Peri-operative Outcomes and Reduced Long-Term Survival after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a Review of 936 Cases.
    Saxena A; Valle SJ; Liauw W; Morris DL
    J Gastrointest Surg; 2017 Aug; 21(8):1318-1327. PubMed ID: 28560703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study.
    Yrjönen A; Koskenvuo L; Haapamäki C; Lepistö A
    Scand J Surg; 2024 Jun; 113(2):140-149. PubMed ID: 37828760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nomogram to Predict Tube Occlusion During Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei.
    Liu Q; Li C; Wang B; Yu G
    J Coll Physicians Surg Pak; 2024 Jul; 34(7):790-794. PubMed ID: 38978242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.